Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib + Corticosteroids in First-Line cGVHD
NCT02701634Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of entospletinib in chronic graft-versus-host disease (cGVHD), sponsored by Gilead Sciences. Started May 2016; status: terminated.
02
Drugs
entospletinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02701634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02701634.